Stay updated with breaking news from Baxter Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On May 28, 2021, the Federal Circuit found obvious the claims of a patent directed to telepharmacy, describing a process allowing a pharmacist to remotely supervise and approve the work of non-pharmacists in filling drug orders.
A weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent...
US Court of Appeals for the Federal Circuit reversed a Patent Trial & Appeal Board decision finding non-obviousness in an inter partes review in Becton, Dickinson, and Co. v. Baxter Corp. Englewood case
In a relatively unusual outcome, the US Court of Appeals for the Federal Circuit reversed a Patent Trial & Appeal Board (Board) decision finding non-obviousness in an inter partes...
ADVERTISEMENT Full Fed. Circ. Won't Review Becton's Wins On Drug Dosing IP Law360 (May 10, 2021, 2:06 PM EDT) -- The full Federal Circuit on Monday denied a petition from Baxter Corp. Englewood for review of a panel decision affirming Patent Trial and Appeal Board rulings that invalidated two of the company's medication dosing patents in challenges brought by Becton Dickinson & Co. The full court denied the bid for rehearing in a two-page order, thereby rejecting Baxter's argument that the PTAB had violated the Administrative Procedure Act because it impermissibly relied on invalidity argume...